Updated:
i&i Bio
i&i Bio is structured as a Luxembourg-based private equity firm focused on early-stage through growth-stage investments in life sciences, with a particular...
i&i Bio
i&i Bio is structured as a Luxembourg-based private equity firm focused on early-stage through growth-stage investments in life sciences, with a particular emphasis on biotechnology and related health sectors. The firm's formation reflects a broader movement in European venture to anchor promising academic discoveries with committed, specialist capital, although specific founding principals and the vehicle's precise inception date remain opaque in public record. Investment activity spans seed, start-up, and growth stages, with the firm targeting co-investment opportunities alongside institutional partners, university technology-transfer offices, and European research consortia. i&i Bio's mandate concentrates on therapeutics, medical devices, and enabling technologies sourced primarily from institutions across the European Union. The firm deploys via direct equity and structured co-investment vehicles, positioning as a specialist rather than a generalist financial sponsor. The firm maintains its registered office in Luxembourg, a jurisdiction that has increasingly attracted private equity and venture structures seeking regulatory passporting benefits across the EU. No public disclosures detail total headcount, committed capital, or specific portfolio companies, reflecting either early-stage organizational maturation or deliberate operational opacity common among specialist investment firms that prioritize deal-level discretion. i&i Bio's structural differentiator rests in its pure-play specialization: unlike diversified European private equity managers that allocate a tranche to life sciences within a multi-sector fund, i&i Bio appears designed exclusively around biotech venture, enabling deeper domain concentration and, presumably, a more technically fluent investment committee equipped to diligence pre-revenue therapeutic assets across the EU's fragmented innovation landscape.
General information
Firm type
Private Equity
Year founded
2021
Location
Region
Europe
Country
Luxembourg
City
Luxembourg
Corporate office
Luxembourg, Luxembourg
Principals
Karel Kubias
Founding Partner
Ivan Vohlmuth
Founding Partner
Barbora Šumová
Partner
Tomáš Maršálek
Founding Partner
Sector focus
Frequently asked questions
Who runs investment decisions at i&i Bio?
Investment decisions are led by Founding Partners Karel Kubias, Ivan Vohlmuth, and Tomáš Maršálek, alongside Partner Barbora Šumová. Kubias brings 20 years of life sciences executive experience, Vohlmuth has overseen over 100 investments across CEE, and Maršálek specializes in fund management and valuations. The team comprises seven professionals including an associate and an advisor.
How does i&i Bio source proprietary deal flow?
The firm is embedded in the innovation ecosystem around the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Science, providing access to preclinical research and academic spinouts. It also scouts broadly across Europe for early-stage life science ventures, focusing on Central and Eastern Europe but open to pan-European opportunities. The portfolio includes companies from drug discovery, medtech, diagnostics, and AI verticals.
Is i&i Bio structured as a single family office or does it operate more like a venture firm?
i&i Bio is structured as a Luxembourg-based venture capital fund, not a family office. The firm operates as a VC focused exclusively on early-stage life sciences, deploying a €53M fund with targeted investments between €150,000 and €2M per round. It is externally managed by a team of seven professionals including founding partners with backgrounds in pharma, private equity, and fund management.
Does i&i Bio participate in fund commitments or only direct deals?
i&i Bio primarily makes direct equity investments in early-stage life science companies. The fund deploys capital at seed, startup, and growth stages, with a sweet spot between €0.5M and €2M for follow-on rounds. It also reserves additional funding for what it calls 'unicorn' portfolio companies, indicating a co-investment or direct-investment strategy rather than a fund-of-funds approach.
What investment stages does i&i Bio typically target?
The fund targets early-stage ventures from seed to growth, with a starting ticket of €150,000 for business creation and a sweet spot between €0.5M and €2M for scaling rounds. Portfolio companies include both preclinical-stage biotech startups and those advancing into clinical trials, such as Captain T Cell and T-CURX. i&i Bio also retains capacity to follow on for exceptional performers.
Which sectors does i&i Bio explicitly focus on?
i&i Bio focuses exclusively on life sciences, with specific verticals including drug discovery, medtech, diagnostics, and AI-driven biotech. The firm explicitly avoids generalist tech or non-life sciences investments. Its portfolio spans drug discovery platforms, medtech devices, diagnostic tools, and AI applications for drug discovery, as reflected in companies like Antiverse, HeartBeat.bio, and Theorema.
Where does the underlying capital for i&i Bio come from?
The source of capital is not publicly disclosed by i&i Bio. The firm operates as a Luxembourg-based venture capital fund with a declared €53M fund. As an external VC, it likely draws from institutional LPs such as pension funds, family offices, or European development institutions, but no specific investors are named on the firm’s website.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: